gainuo (vinorelbine tartrate injection)-比较正规的买球软件

中

about us
- founded in 1995, hansoh is a leading r&d-driven pharmaceutical company in china.
- founded in 1995, hansoh is a leading r&d-driven pharmaceutical company in china.
- founded in 1995, hansoh is a leading r&d-driven pharmaceutical company in china.
- founded in 1995, hansoh is a leading r&d-driven pharmaceutical company in china.
- founded in 1995, hansoh is a leading r&d-driven pharmaceutical company in china.
news
- company news
- media focus
- with the objective of 'creating excellence in china's pharmaceuticals and add momentum to "made in china"',hansoh endeavors to make its own contribution to the “healthy china 2030” master plan.
- with the objective of 'creating excellence in china's pharmaceuticals and add momentum to "made in china"',hansoh endeavors to make its own contribution to the “healthy china 2030” master plan.
products
- hansoh is committed to innovation and research in the six therapeutic areas, including cns, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. constantly evolving, hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- hansoh is committed to innovation and research in the six therapeutic areas, including cns, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. constantly evolving, hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- hansoh is committed to innovation and research in the six therapeutic areas, including cns, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. constantly evolving, hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- hansoh is committed to innovation and research in the six therapeutic areas, including cns, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. constantly evolving, hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- hansoh is committed to innovation and research in the six therapeutic areas, including cns, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. constantly evolving, hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- hansoh is committed to innovation and research in the six therapeutic areas, including cns, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. constantly evolving, hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
r&d
- hansoh has been holding on to the strategy of technology and innovation, and established r&d centers located in lianyungang and shanghai.
- hansoh has been holding on to the strategy of technology and innovation, and established r&d centers located in lianyungang and shanghai.
- hansoh has been holding on to the strategy of technology and innovation, and established r&d centers located in lianyungang and shanghai.
- hansoh has been holding on to the strategy of technology and innovation, and established r&d centers located in lianyungang and shanghai.
services
- hansoh pursuits the philosophy of “professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- hansoh pursuits the philosophy of “professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- hansoh pursuits the philosophy of “professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate
contact us
- hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.

gainuo (vinorelbine tartrate injection)

vinorelbine tartrate injection

english name: vinorelbine tartrate injection

chinese pinyin: jiushisuan changchunruibin zhusheye

the main ingredient of this product is vinorelbine tartrate.

chemical name: 3',4'-dihydro--4'-deoxy-8'-norvinine ditartrate.

/en/upload/images/2017/10/10/41d2df938ded495a86bfaa0c5ad057da.png

【name】	common name: vinorelbine tartrate injection brand name: gainuo english name: vinorelbine tartrate injection chinese pinyin: jiushisuan changchunruibin zhusheye
【ingredients】	the main ingredient of this product is vinorelbine tartrate. chemical name: 3',4'-dihydro--4'-deoxy-8'-norvinine ditartrate. chemical structure: molecular formula: c₄₅h₅₄n₄o₈ .2c₄h₆o₆ molecular weight: 1079.12 excipients: water for injectio
【description】	this product is a colorless to yellowish clear liquid.
【indications】	this product is suitable for patients with non-small cell lung cancer and breast cancer.
【strength】	1ml:10mg（calculated on c₄₅h₅₄n₄o₈）.
【dosage and administration】	for intravenous use only. single-agent: the recommended dose is 25 to 30 mg/m2 weekly. multidrug therapy:dosage and dosing time are chosen according to the protocol used. the dose is usually 25 to 30 mg/m2. the drug must be dissolved in physiological saline, intravenously administered in a short period of time (15 to 20 minutes), and then intravenously rinsed with saline.

1999: first-to-market generic drug in china

2002: national key new product

2012: approval (lyophilized powder) from us fda